Antifungal Consumption in Hematology, Intensive Care Units and at Hospital Level in French Hospitals in 2024
Abstract
OBJECTIVES: In healthcare facilities, the expanding population of immunocompromised patients, associated with the emergence of antifungal-resistant pathogens, highlights the need for surveillance of antifungal consumption. This study aimed to provide an updated overview of systemic antifungal use in French hospitals, with a particular focus on haematology wards and intensive care units (ICUs). METHODS: A retrospective study was conducted among voluntary hospitals using the national surveillance methodology. Data included quantities of antifungals dispensed in inpatient wards at hospital level, ICUs, and haematology wards, as well as the number of patient-days (PD). Consumption was expressed as defined daily doses (DDD) per 1000 PD. RESULTS: A total of 684 hospitals participated, including 33 haematology wards and 139 ICUs. Overall antifungal consumption was 15.7 DDD/1000 PD, with higher consumption in haematology wards (355.8 DDD/1000 PD) and ICUs (130.2 DDD/1000 PD). The most frequently used antifungal agents were fluconazole (49.8%), posaconazole (16.3%), and caspofungin (15.7%). In ICUs, fluconazole (38.6%), caspofungin (31.8%), and voriconazole (9.0%) predominated, whereas in haematology wards posaconazole (43.7%) was the most used antifungal, followed by fluconazole (24.1%) and voriconazole (12.3%). Antifungal consumption varied among wards and hospitals. CONCLUSIONS: Consumption patterns were consistent with current recommendations. Variations between wards may reflect differences in patient populations and prophylactic or therapeutic prescribing practices. Continued national surveillance, combined with prescribing practice evaluations and studies of local fungal ecology, will contribute to optimising antifungal prescribing.
Related
- Assessing Bacterial contaminants on hospital devices at Zomba Central Hospital Intensive care Unit (ICU) and Theatre.
- Adverse events and associated factors during intra-hospital transport of mechanically ventilated intensive care patients
- Birth prevalence and characteristics of cleft lip and/or palate in dubai health public hospitals, 2018-2025: a retrospective hospital-based study.
- CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
- Dietary hot red pepper powder modulates laying performance, hematology profile, and hepatic antioxidant status in laying hens under tropical conditions.
BibTeX
@article{gressanipellerin2026antifungal,
title = {{Antifungal Consumption in Hematology, Intensive Care Units and at Hospital Level in French Hospitals in 2024}},
author = {Justine Gressani-Pellerin and Ségolène Bougès and Olivia Ali-Brandmeyer and Amélie Jouzeau and Lory Dugravot and Yasmine Nivoix and Florence Colas and Loïc Simon and Catherine Dumartin},
journal = {Journal of Global Antimicrobial Resistance},
year = {2026},
month = oct,
doi = {10.1016/j.jgar.2026.09.003},
url = {https://hal.science/hal-05784428v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Antifungal Consumption in Hematology, Intensive Care Units and at Hospital Level in French Hospitals in 2024
AU - Justine Gressani-Pellerin
AU - Ségolène Bougès
AU - Olivia Ali-Brandmeyer
AU - Amélie Jouzeau
AU - Lory Dugravot
AU - Yasmine Nivoix
AU - Florence Colas
AU - Loïc Simon
AU - Catherine Dumartin
PY - 2026
DA - 2026/10/07
JO - Journal of Global Antimicrobial Resistance
DO - 10.1016/j.jgar.2026.09.003
UR - https://hal.science/hal-05784428v1
AB - OBJECTIVES: In healthcare facilities, the expanding population of immunocompromised patients, associated with the emergence of antifungal-resistant pathogens, highlights the need for surveillance of antifungal consumption. This study aimed to provide an updated overview of systemic antifungal use in French hospitals, with a particular focus on haematology wards and intensive care units (ICUs). METHODS: A retrospective study was conducted among voluntary hospitals using the national surveillance methodology. Data included quantities of antifungals dispensed in inpatient wards at hospital level, ICUs, and haematology wards, as well as the number of patient-days (PD). Consumption was expressed as defined daily doses (DDD) per 1000 PD. RESULTS: A total of 684 hospitals participated, including 33 haematology wards and 139 ICUs. Overall antifungal consumption was 15.7 DDD/1000 PD, with higher consumption in haematology wards (355.8 DDD/1000 PD) and ICUs (130.2 DDD/1000 PD). The most frequently used antifungal agents were fluconazole (49.8%), posaconazole (16.3%), and caspofungin (15.7%). In ICUs, fluconazole (38.6%), caspofungin (31.8%), and voriconazole (9.0%) predominated, whereas in haematology wards posaconazole (43.7%) was the most used antifungal, followed by fluconazole (24.1%) and voriconazole (12.3%). Antifungal consumption varied among wards and hospitals. CONCLUSIONS: Consumption patterns were consistent with current recommendations. Variations between wards may reflect differences in patient populations and prophylactic or therapeutic prescribing practices. Continued national surveillance, combined with prescribing practice evaluations and studies of local fungal ecology, will contribute to optimising antifungal prescribing.
SN - 2213-7165
SN - 2213-7173
ER -